UA125474U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis involves clinical examination, examination of low and high density lipoprotein cholesterol, arteriography. Serum polymorphism of the eNOS T786C gene, endothelin content, SICP, oxyproline, PSA, homocysteine is determined in the serum. With homozygous carrier 786-SS, endothelin levels> 10 ng / ml, SICP <102 ng / ml, oxyproline> 15 μmol / l, SRP> 6 mg / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (AN Okorokov.

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the nitric oxide synthase gene (eMmoO5 T786C), the content of endothelin, C-terminal propeptide of type I collagen (SICP), oxyproline, C -reactive protein (SRP), homocysteine.

With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, oxyproline "15 μmol/l, SRP "6 mg/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method.

During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the blood serum of the patient, the polymorphism of the emo T786C gene is determined, and the content of endothelin, SISR, oxyproline, SRP, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, oxyproline 215 μmol/l, SRP "6b mg/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient K., 55 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed. No signs of atherosclerosis were found. The eMmoz T786C gene polymorphism was determined in blood serum. The content of endothelin, SISR, oxyproline,

SRP, homocysteine. Homozygous carrier 786-SS was established. Endothelin levels - 14.8 ng/ml,

SICP - 80 ng/ml, oxyproline - 28 μmol/l, SRP - 15 mg/l, homocysteine - 26 μmol/l.

The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 13 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

FORMULA OF A USEFUL MODEL Method of diagnosing the development of atherosclerosis, which includes conducting a clinical examination, 40 studies of the level of low- and high-density lipoprotein cholesterol, arteriography, which is distinguished by the fact that the eMO5 1786C gene polymorphism, the content of endothelin, SISR, oxyproline, SRP, homocysteine are determined in the blood serum, and in the case of homozygous carrier 786-SS, at endothelin levels »10 ng /ml, SISR "102 ng/ml, oxyproline "15 μmol/l, SRP "6b mg/l, homocysteine 220 μmol/l diagnose the development of atherosclerosis.